INVO Bioscience, Inc. (INVO)
Market Cap | 7.62M |
Revenue (ttm) | 3.59M |
Net Income (ttm) | -8.27M |
Shares Out | 12.59M |
EPS (ttm) | -0.64 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 65,424 |
Open | 0.605 |
Previous Close | 0.605 |
Day's Range | 0.605 - 0.640 |
52-Week Range | 0.329 - 2.837 |
Beta | 0.80 |
Analysts | Sell |
Price Target | 2.04 (+237.02%) |
Earnings Date | May 15, 2023 |
About INVO
INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida. [Read more]
Financial Performance
In 2021, INVO's revenue was $4.16 million, an increase of 301.06% compared to the previous year's $1.04 million. Losses were -$6.65 million, -20.27% less than in 2020.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for INVO stock is "Sell." The 12-month stock price forecast is $2.04, which is an increase of 237.02% from the latest price.
News

INVO Bioscience Announces Closing of $3.0 Million Registered Direct Offering
SARASOTA, Fla. , March 27, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment w...

INVO Bioscience Announces Pricing of $3.0 Million Registered Direct Offering Priced At-The-Market
SARASOTA, Fla. , March 24, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment w...

INVO Signs Binding Agreements to Acquire Wisconsin Fertility Institute
Accretive acquisition expected to add significant scale to INVO's operations Contributes over $5 million in incremental annual revenue as well as positive net income Initial transaction that establis...

INVO Bioscience Enters Distribution Agreement for Taiwan
SARASOTA, Fla. , Jan. 5, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment wor...

INVO Bioscience Engages Nationally Recognized Physician for New Tampa-based INVO Center
Shelly W. Holmström, M.D. FACOG, to serve as physician operator at soon to be opened Tampa-based INVO Center.

First Baby Born in Malaysia Utilizing Innovative INVOcell Assisted Reproductive Technology
Patient was part of a prospective peer reviewed study of INVOcell compared to conventional IVF (cIVF) in Malaysia INVOcell provides an advanced, effective and affordable infertility treatment option t...

INVO Bioscience Reports Third Quarter 2022 Financial Results
Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla. , Nov. 14, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company f...

INVO Bioscience to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , Nov. 10, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-sta...

INVO Bioscience Highlights INVOcell Progress From the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo
- The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030, yet remains severely underserved with many patients (upwards of 90% by many estimate...

INVOcell Review Published in Current Opinion in Obstetrics and Gynecology
SARASOTA, Fla. , Oct. 21, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ...

INVO Bioscience to Exhibit at the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo
SARASOTA, Fla. and ANAHEIM, Calif.

Invo BioScience Inc. (INVO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Invo BioScience Inc. (INVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement...

Dr. Sue Ellen Carpenter of INVO Bioscience's Atlanta-based INVO Center - Bloom Fertility - Named Top Doctor by Castle Connolly
SARASOTA, Fla. and ATLANTA , Sept.

Invo BioScience Inc. (INVO) Upgraded to Buy: Here's What You Should Know
Invo BioScience Inc. (INVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

INVOcell Launched in Malaysia by Advanced Reproductive Centre, Hospital Canselor Tuanku Muhriz
SARASOTA, Fla. , Aug. 25, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ...

INVO Bioscience Reports Second Quarter 2022 Financial Results
Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla. , Aug. 15, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company f...

INVO Bioscience to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , Aug. 4, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stag...

INVO Bioscience Announces "Get to Know INVOcell" - a Series of Facebook Live Events Supporting Access to Affordable Fertility Treatment
Mark Your Calendars for July 7, 2022, with Dr. Sue Ellen Carpenter of Atlanta-based Bloom Fertility SARASOTA, Fla. , July 7, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "C...

INVO Signs Distribution Agreement with Onesky Holding Limited for Mainland China
Agreement includes minimum purchase obligations upon product registration and approval SARASOTA, Fla. , May 16, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a c...

INVO Bioscience Reports First Quarter 2022 Financial Results
Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., May 16, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company foc...

INVO Bioscience to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , May 9, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage...

INVO Celebrates National Infertility Awareness Week at the INVO Center in Atlanta, Georgia
Bloom Fertility, an INVO Center to grant three eligible patients a full IVC treatment cycle SARASOTA, Fla. , April 28, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fer...

INVO Selects Kansas City as additional INVO Center Location
U.S. Market Expansion Continues as Planned SARASOTA, Fla. , April 14, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused ...

INVO Bioscience to Participate in the Lytham Partners Spring 2022 Investor Conference
SARASOTA, Fla. , April 4, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell®...

INVO Bioscience Reports 2021 Financial Results
Company to Host Conference Call Today at 4:30pm ET; Slide Presentation Also Available SARASOTA, Fla. , March 31, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a ...